About: GSK2831781

An Entity of Type: monoclonal antibody, from Named Graph: http://dbpedia.org, within Data Space: dbpedia.org

GSK2831781 is a monoclonal antibody being developed by GlaxoSmithKline (GSK) for autoimmune diseases. The antibody targets the T cell activation marker LAG-3, which is mainly expressed in inflamed tissues. In GSK's March 2015 Product development pipeline document the antibody is listed under 'Immuno-inflammation' candidates. GSK2831781 entered a Phase I clinical trial in psoriasis early in 2015.

Property	Value
dbo:abstract	GSK2831781 is a monoclonal antibody being developed by GlaxoSmithKline (GSK) for autoimmune diseases. The antibody targets the T cell activation marker LAG-3, which is mainly expressed in inflamed tissues. In GSK's March 2015 Product development pipeline document the antibody is listed under 'Immuno-inflammation' candidates. GSK2831781 entered a Phase I clinical trial in psoriasis early in 2015. (en)
dbo:casNumber	2088304-32-7
dbo:wikiPageID	46545835 (xsd:integer)
dbo:wikiPageLength	8822 (xsd:nonNegativeInteger)
dbo:wikiPageRevisionID	1106163780 (xsd:integer)
dbo:wikiPageWikiLink	dbr:Psoriasis dbr:Antibody-dependent_cellular_cytotoxicity dbr:Cytotoxicity dbr:University_of_Nantes dbc:Experimental_drugs dbr:Complement_system dbr:Corticosteroids dbr:Type_IV_hypersensitivity dbr:Frédéric_Triebel dbr:GlaxoSmithKline dbr:Monoclonal_antibody dbr:Murine dbr:Contract_research_organization dbr:Clinical_and_Experimental_Immunology dbr:Clinical_endpoint dbr:Proof_of_concept dbr:T_helper_cell dbr:Medical_literature dbr:BCG_vaccine dbr:Tuberculin dbr:Fusion_protein dbr:France dbr:Northwick_Park_Hospital dbr:Fragment_crystallizable_region dbr:Prima_BioMed dbr:Transplant_rejection dbc:Monoclonal_antibodies dbr:Afucosylated_monoclonal_antibodies dbr:LAG3 dbr:Biotechnology dbr:TNF dbr:Transplantation_(journal) dbr:INSERM dbr:Plaque_psoriasis dbr:Humanized_antibody dbr:Autoimmune_diseases dbr:Immunoglobulin_G dbr:T_cell dbr:PAREXEL dbr:LAG-3 dbr:IMP731
dbp:casNumber	2088304 (xsd:integer)
dbp:legalStatus	Investigational (en)
dbp:type	mab (en)
dbp:wikiPageUsesTemplate	dbt:Infobox_drug dbt:Reflist dbt:Short_description
dcterms:subject	dbc:Experimental_drugs dbc:Monoclonal_antibodies
gold:hypernym	dbr:Antibody
rdf:type	owl:Thing dul:ChemicalObject dbo:ChemicalSubstance wikidata:Q8386 dbo:MonoclonalAntibody dbo:Drug
rdfs:comment	GSK2831781 is a monoclonal antibody being developed by GlaxoSmithKline (GSK) for autoimmune diseases. The antibody targets the T cell activation marker LAG-3, which is mainly expressed in inflamed tissues. In GSK's March 2015 Product development pipeline document the antibody is listed under 'Immuno-inflammation' candidates. GSK2831781 entered a Phase I clinical trial in psoriasis early in 2015. (en)
rdfs:label	GSK2831781 (en)
owl:sameAs	freebase:GSK2831781 yago-res:GSK2831781 wikidata:GSK2831781 https://global.dbpedia.org/id/uPZE
prov:wasDerivedFrom	wikipedia-en:GSK2831781?oldid=1106163780&ns=0
foaf:isPrimaryTopicOf	wikipedia-en:GSK2831781
is dbo:product of	dbr:Immutep
is dbo:wikiPageWikiLink of	dbr:List_of_human_clusters_of_differentiation dbr:Immutep dbr:Lymphocyte-activation_gene_3
is foaf:primaryTopic of	wikipedia-en:GSK2831781